A Phase 2B, Non-Randomized, Controlled, Open-Label, Extension Study to Evaluate the Persistence of Immune Response of the Adjuvated RSVPREF3 Vaccine and the Safety and Immunogenicity Following Revaccination in Lung and Kidney Transplant Recipients (>=18 y

Grants and Contracts Details

StatusActive
Effective start/end date11/13/25 → 11/13/27

Funding

  • Corixa Corporation: $2.00